Michael Parini - 01 Sep 2026 Form 4 Insider Report for BIOGEN INC. (BIIB)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Sep 2026, 16:14:24 UTC
Prior SEC filing
12 Aug 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Bryan Keighery, attorney-in-fact for Mr. Parini

Key filing fact

Michael Parini filed Form 4 for BIOGEN INC. (BIIB) on 03 Sep 2026.

Key facts

  • This page summarizes Michael Parini's Form 4 filing for BIOGEN INC. (BIIB).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Sep 2026, 16:14.

Change

  • Previous filing in this sequence was filed on 12 Aug 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001661567 Primary reporting owner

Parini Michael

Relationship
Chief Legal Officer
Address
225 BINNEY STREET, CAMBRIDGE
Signature
/s/ Bryan Keighery, attorney-in-fact for Mr. Parini
Signature date
03 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIIB transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares
+7,405
Change %
Price
$0.000000*
Shares after
7,405
Date
01 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,405
Exercise price
$0.000000
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .